CORONA Remedies promoter confirms no encumbrance on shares in FY26

1 min read     Updated on 04 Jun 2026, 09:30 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Dr. Kirtikumar Mehta, Promoter of CORONA Remedies Limited, confirmed in a filing to stock exchanges that he and Persons Acting in Concert have not encumbered any equity shares held directly or indirectly during FY26. The disclosure, dated April 01, 2026, was made under Regulation 31(4) of SEBI SAST Regulations and lists 23 individuals and entities in the promoter group.

powered bylight_fuzz_icon
42134413

*this image is generated using AI for illustrative purposes only.

Dr. Kirtikumar Mehta, Promoter of corona remedies , has declared that he and Persons Acting in Concert have not made any encumbrance on the equity shares held by them during the financial year 2025-2026. The disclosure, submitted to BSE Limited and National Stock Exchange of India Limited, confirms that the shares held directly or indirectly by the promoter group remain free of charges or liens. This filing was made pursuant to Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The declaration encompasses the promoter and the broader promoter group, including various individuals and entities listed as Persons Acting in Concert. The list includes family members such as Nirav Mehta and Ankur Mehta, as well as corporate entities like NKM Nextgen LLP and KLNext Enterprise LLP. The submission was addressed to the Department of Corporate Relations at BSE and the Department of Corporate Services at NSE on April 01, 2026.

Persons Acting in Concert

The following table details the individuals and entities covered under the declaration:

Sr. No. Name
Promoter
1. Nirav Mehta
2. Ankur Mehta
Promoter Group
3. Minaxi Kirtikumar Mehta
4. Deepa Nirav Mehta
5. Brinda Ankur Mehta
6. Hetvi Nirav Mehta
7. Vanshaj Niravkumar Mehta
8. Jitendrakumar Champaklal Vora
9. Chandrika Jitendrakumar Vora
10. Nehal Devang Vora
11. Heti Darshan Kothari
12. Vishwa Ankur Mehta
13. Jainam Ankur Mehta
14. Subodhbhai Vrajlal Parikh
15. Shardaben Subodhbhai Parikh
16. Pritesh Subodhbhai Parikh
17. Kanakben Arvindbhai Shah
18. Vasumatiben Kirtibhai Shah
19. Yogeshbhai Harilal Shah
20. Ketan Harilal Shah
21. Nemish Harilal Shah
22. NKM Nextgen LLP
23. KLNext Enterprise LLP

The declaration was signed by Dr. Kirtikumar Mehta, Chairman of CORONA Remedies Limited, and copies were forwarded to the Chairman of the Audit Committee and the Company Secretary and Compliance Officer.

Historical Stock Returns for Corona Remedies

1 Day5 Days1 Month6 Months1 Year5 Years
+1.39%+2.97%-0.32%+19.92%+19.92%+19.92%

Does the unencumbered status of promoter shares indicate a potential plan to raise capital through pledging in the future?

How might this clean shareholding structure influence investor confidence and stock liquidity in the upcoming fiscal year?

Could this declaration be a precursor to a strategic acquisition or a stake sale by the promoter group?

Corona Remedies to hold investor meetings in Singapore on June 8

1 min read     Updated on 04 Jun 2026, 03:12 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

CORONA Remedies Limited announced it will conduct a Non-Deal Roadshow with 1x1 investor meetings in Singapore on June 8 and June 9, 2026, starting at 09:00 A.M. (SST). Organized by IIFL Capital, the discussions will rely solely on publicly available information without sharing any unpublished price sensitive information (UPSI). The regulatory filing, submitted on June 3, 2026, under Regulation 30 of the SEBI Listing Obligations Regulations, notes that the schedule is subject to change due to exigencies.

powered bylight_fuzz_icon
42004494

*this image is generated using AI for illustrative purposes only.

CORONA Remedies Limited will hold a series of investor meetings in Singapore on June 8 and June 9, 2026, as part of a Non-Deal Roadshow (NDR). The meetings, scheduled to begin at 09:00 A.M. (SST), are organized by IIFL Capital and will involve 1x1 interactions with investors. The company disclosed this schedule in a regulatory filing submitted on June 3, 2026.

The discussions during these meetings will be strictly based on publicly available information. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the interactions. This initiative is part of the company's ongoing engagement with the investment community.

The schedule for the meetings is detailed below:

Date and Time Organized by Nature of Meeting Place
June 08, 2026 and June 09, 2026
09:00 A.M. (SST) Onwards
IIFL Capital 1x1 Meeting Singapore

The filing was submitted pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company.

Chetna Prabhat Kumar Dharajiya, Company Secretary and Compliance Officer, signed the intimation on behalf of CORONA Remedies Limited. The information is also available on the company's official website.

Historical Stock Returns for Corona Remedies

1 Day5 Days1 Month6 Months1 Year5 Years
+1.39%+2.97%-0.32%+19.92%+19.92%+19.92%

What strategic priorities is CORONA Remedies likely to emphasize during these investor meetings?

How might the outcomes of these meetings influence the company's future investor engagement strategies?

Could this roadshow signal potential upcoming capital raising activities or partnerships?

More News on Corona Remedies

1 Year Returns:+19.92%